GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2014

Sanofi, UCB to Hunt for Small Molecules for Immune-Mediated Diseases

  • UCB and Sanofi are teaming up to look for and develop anti-inflammatory small molecules that could be used to treat a range of immune-mediated diseases in areas that include gastroenterology and arthritis. Per the agreement, the two firms will share costs and profits on a 50/50 basis, and UCB will be entitled to initial upfront, preclinical, and clinical development milestone payments—ones potentially worth over €100 million ($138.5 million)—from Sanofi.

    UCB's research arm, UCB NewMedicines, has come up with a way to identify small molecule modulators of a biological pathway for which parenterally administered biologic therapies have reportedly proven effective in patients. Sanofi and UCB plan to assemble and lead together a team of scientists that will characterize and identify potential new treatments.

    "We partner Sanofi’s significant expertise, strong capabilities and resources with UCB’s cutting-edge research skills and breakthrough innovations," Ismail Kola, president of UCB NewMedicines, said in a statement. "Together we can maximize the opportunity to treat diseases currently treated by biologic agents with small molecules and thus benefit millions of people suffering from severe diseases."



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?